2
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Multiple Myeloma
14
Lymphoma, Non-Hodgkin
10
Carcinoma, Non-Small-Cell Lung
7
Breast Neoplasms
7
Arthritis, Rheumatoid
7
Lymphoma, Large B-Cell, Diffuse
5
Lymphoma, B-Cell
5
Lymphoma
5
Solid Tumors
4
Recurrence
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Neoplasms
4
Melanoma
4
Leukemia, Myeloid, Acute
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Colorectal Neoplasms
4
Ovarian Neoplasms
3
Lymphoma, Follicular
3
Leukemia
3
Hematologic Neoplasms
3
Cytokine Release Syndrome
3
Burkitt Lymphoma
3
Urinary Bladder Neoplasms
2
Respiratory Distress Syndrome
2
Pancreatic Neoplasms
2
Myelodysplastic Syndromes
2
Lymphoma, Mantle-Cell
2
Fallopian Tube Neoplasms
2
Craniopharyngioma
2
Carcinoma, Hepatocellular
2
Interventions
rozanolixizumab
11
efgartigimod alfa
10
zilucoplan
8
Prednisone
8
Cyclophosphamide
8
ravulizumab
7
Rituximab
7
Pyridostigmine Bromide
7
telitacicept
6
fludarabine
6
Tacrolimus
6
Mycophenolic Acid
6
eculizumab
5
Immunoglobulins, Intravenous
5
Hizentra
4
Azathioprine
4
Steroids
3
HBM9161
3
Data Collection
3
Amifampridine
3
thymoglobulin
2
inebilizumab
2
Thymectomy
2
Prednisolone
2
Methylprednisolone
2
Methotrexate
2
Exercise
2
Diagnostic Self Evaluation
2
Blood Specimen Collection
2
tofacitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myasthenia Gravis
×
tocilizumab
×
Clear all
NCT05716035
2024-01-22
tMG-E
Tang-Du Hospital
Phase 2/3
Unknown
64 enrolled